Can a lower dose of avastin save sight in preemies?
NCT ID NCT04634578
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This study tests whether lower doses of the drug bevacizumab (Avastin) can effectively treat a severe form of retinopathy of prematurity (ROP) in premature infants. The trial includes 77 babies with type 1 ROP in zone I, the most dangerous type. Each infant receives a single injection of either 0.063 mg or 0.25 mg of bevacizumab into the affected eye(s). The main goal is to see if the disease improves within 4 weeks without needing additional treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINOPATHY OF PREMATURITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611, United States
-
Arkansas Childrens Hospital/ University of Arkansas Medical Sciences
Little Rock, Arkansas, 72202, United States
-
Boston Children's Hospital
Boston, Massachusetts, 02215, United States
-
Casey Eye Institute
Portland, Oregon, 97239, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Cincinnati Children's Hospital
Cincinnati, Ohio, 45229, United States
-
Duke University Eye Center
Durham, North Carolina, 27710, United States
-
Greater Baltimore Medical Center
Baltimore, Maryland, 21204-5809, United States
-
IWK Health Centre
Halifax, Nova Scotia, B3K 6R8, Canada
-
Indiana University School of Medicine
Indianapolis, Indiana, 46202, United States
-
Jules Stein Eye Institute at the University of California, Los Angeles
Los Angeles, California, 90095, United States
-
New York Presbyterian David H Koch Center
New York, New York, 10065, United States
-
Pediatric Ophthalmology Associates, Inc.
Columbus, Ohio, 43205, United States
-
Riley Hospital for Children
Indianapolis, Indiana, 46202, United States
-
Storm Eye Institute
Mt. Pleasant, South Carolina, 29464, United States
-
Texas Children's Hospital - Dept. Of Ophthalmology
Houston, Texas, 77030, United States
-
The Emory Eye Center
Atlanta, Georgia, 30322, United States
-
U of Illinois at Chicago Eye and Ear Infirmary
Chicago, Illinois, 60612, United States
-
UK Ophthalmology and Visual Sciences, The Eye Clinic
Lexington, Kentucky, 40508, United States
-
UPMC Children's Eye Center of Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15224, United States
-
Univ of California, Irvine- Gavin Herbert Eye Institute
Irvine, California, 92697, United States
-
University of California San Francisco Department of Ophthalmology
San Francisco, California, 94143, United States
-
University of California, Davis
Sacramento, California, 95817, United States
-
University of Chicago
Hyde Park, Illinois, 60637, United States
-
University of Utah Moran Eye Center
Salt Lake City, Utah, 84132, United States
-
Virginia Pediatric Eye Center
Norfolk, Virginia, 23502, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab (Avastin) injection into the eye
What this could lead to
If successful, this could show that lower doses of bevacizumab are effective for severe ROP, potentially reducing side effects while still saving sight.
What could go wrong
This is a small Phase 2 trial with only 77 infants, so results may not apply to all cases. Lower doses might not work as well as standard doses, and recurrence of ROP is possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.